What Happened

The FDA approved zilurgisertib (Atebrioz), an oral ALK2 inhibitor developed by Mirum Pharmaceuticals under license from Incyte, for fibrodysplasia ossificans progressiva (FOP) in patients aged 12 years and older. The approval, announced September 25, 2026, is based on the randomized, double-blind, placebo-controlled Phase 2 PROGRESS trial. At week 24, patients receiving zilurgisertib had a mean decrease of 3.2 cm³ in total new heterotopic ossification volume, compared with a mean increase of 24.6 cm³ in the placebo group (nominal P = .004). The recommended starting dosage is 100 mg orally once daily.

Who Is Affected

Mirum Pharmaceuticals is the primary beneficiary as the drug's developer and commercializer. The approval also involves Incyte, which licensed the compound to Mirum. Patients aged 12 and older with FOP now have a new oral treatment option, joining two previously approved therapies. Mirum's commercial operations team will be responsible for launch execution, including sales force deployment, market access negotiations, and patient support programs.

Market Impact

• Sales enablement: Mirum needs to train and equip a sales force to promote Atebrioz to specialists treating FOP.
• Market access and pricing: The company must secure payer coverage and set pricing in a competitive landscape with two other approved FOP therapies.
• Patient support: Launch requires patient assistance programs and adherence tools for a rare disease with high unmet need.
• Real-world evidence: Ongoing pediatric cohorts (ages 6–12 and 2–6) create data collection and RWE needs for potential label expansion.
• Pharmacovigilance: Post-marketing safety monitoring is required, especially given the embryo-fetal toxicity warning.

What to Watch

Additional PROGRESS cohorts are evaluating zilurgisertib in children aged 6 to younger than 12 years and in children aged 2 to younger than 12 years, which could expand the label. Mirum's commercial launch execution, including payer negotiations and sales force ramp-up, will determine near-term revenue trajectory. Also monitor competitive dynamics as garetosmab (Pasatru) was approved in August 2026 for adults only, while palovarotene (Sohonos) has been on the market since 2023.

Related coverage

• Electra raises $350M in IPO, testing appetite for clinical-stage biotech
• FDA advisory panel recommends approval of Grail's multi-cancer blood test Galleri
• Ultragenyx Gene Therapy Fayuvi Receives FDA Approval for Sanfilippo Syndrome
• FDA Clears Neptune Medical's Triton 1 Robotic Endoscopy System for Colon Procedures